Pepromene Bio, Inc. announced a complete response in the first patient treated in the phase 1 B-cell non-Hodgkin’s lymphoma (B-NHL) clinical trial PMB-CT01 (BAFFR-CAR T cells) at City of Hope
IRVINE, California, December 20, 2022 /CNW/ — PeproMene Bio, Inc., a clinical biotechnology company developing novel therapies for the treatment of cancer and immune disorders, today announced that the first patient has been treated for stage 1 relapsed or refractory B-cell non-Hodgkin’s lymphoma (r /r B-NHL) clinical trial PMB-CT01 (BAFFR-CAR T cells) achieved a complete …